Esma Herzel

TL;DR: In this article, a real-world dataset of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test results after inoculation with the BNT162b2 messenger RNA vaccine was analyzed, and the authors found that the viral load was substantially reduced for infections occurring 12-37 days after the first dose of vaccine.

TL;DR: In this article, the effectiveness of the BNT162b2 vaccine in preventing disease and reducing viral loads of breakthrough infections (BTIs) has been decreasing, concomitantly with the rise of the Delta variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

TL;DR: In this paper, the authors analyzed vaccination records and test results collected during the rapid vaccine rollout in a large population from 177 geographically defined communities, and found that the rates of vaccination in each community are associated with a substantial later decline in infections among a cohort of individuals aged under 16 years, who are unvaccinated.

TL;DR: In this paper, a multivariable logistic regression analysis approach was applied to a large patient-level dataset, including SARS-CoV-2 tests, vaccine inoculations and personalized demographics.

TL;DR: In this article, the authors analyzed positive SARS-CoV-2 test results following inoculation with the BNT162b2 mRNA vaccine, and found that the viral load is reduced 4-fold for infections occurring 12-28 days after the first dose of vaccine.